Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257131 | 0.85 | PTGS2 (0.43) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL166762 | 0.85 | PTGS2 (0.43) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL257159 | 0.85 | PTGS2 (0.43) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL882938 | 0.83 | PTGS2 (0.42) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL12669730 | 0.83 | PTGS2 (0.42) | PTGS2PTGS1CA12CA1CA2 | |
| Cadaverine Tartrate SCHEMBL1666549 | 0.77 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL12367200 | 0.75 | PTGS2 (0.41) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL256549 | 0.75 | CA12 (0.43) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL165364 | 0.75 | CA12 (0.43) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL13396347 | 0.74 | CA12 (0.43) | PTGS2PTGS1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150093338-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | FARBER MICHAEL (US) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150093338-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | NOS2, NOS1, NOS3 | PTGS2 145/4885PTGS1 84/4885CA12 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.